Touchstone Sands Capital US Select Growth ETF
TSEL$27.60 +0.42 (1.55%)
Company News
SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients
SpyGlass Pharma, a private ophthalmic biotech company, raised $75 million in Series D funding to advance its drug delivery platform for glaucoma treatment through Phase III trials. The platform aims to provide multiple years of therapy, addressing the need for long-term management of chronic eye diseases.
